Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
fresenius kabi india
3x10 capsule
Thalidomide
Keep in cold place
Delivering To:
Overview
Thalix 50mg Capsule is an immunomodulatory agent. It is used in the treatment of multiple myeloma and lepra reactions. This medicine kills the cancer cells and helps to prevent their growth in the body. It is important to take this medicine as prescribed by your doctor. After the oral administration, the effect of this medicine can be observed in 2-5 hours.
Blood Cancer
Thalix 50mg Capsule shows some side effects. Some of the mild ones do not need any medical attention, and they go away as the body adapts to the medicine. It is important to consult your doctor if they persist for a longer time and are deteriorating your health:
Common side effects include:
Dizziness
Chest pain
Headache
Muscle weakness
Anxiety
Blood clots
Fever
Weight gain
Fatigue
Constipation
Decreased white blood cell count
Swelling
Loss of appetite
Irregular heartbeat
Nausea
Inform your doctor immediately if you experience any persistent or unusual side effects.
The doctor determines the dosage and duration of treatment with Thalix 50mg Capsule as per the patient's health condition. This medicine should be taken orally at the same time every day. Take it as a whole and don't crush or chew the medicine. This tablet can be taken with or without food. It is advised to take this medicine after consulting your healthcare expert.
Thalix 50mg Capsule is an immunomodulatory agent that works by modulating the activity of the body's immune system and helps in indirectly attacking the cancer cells. This medicine stops the growth of blood vessels in cancer, inhibits the multiplication of cancer cells, and stimulates the immune system to attack cancer cells. This is how it treats and manages Multiple Myeloma and Lepra reactions.
Alcohol
unsafe
Avoid the consumption of alcohol while taking Thalix 50mg Capsule, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms
Pregnancy
consult your doctor
Do not take Thalix 50mg Capsule without consulting the doctor in case of pregnancy, as it is an unsafe medicine during this period.
Breast Feeding
consult your doctor
Thalix 50mg Capsule is unsafe to use during breastfeeding as it may cause toxicity to the baby.
Driving
danger
Thalix 50mg Capsule may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
caution
Thalix 50mg Capsule is safe for use in kidney disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
Liver
caution
Thalix 50mg Capsule is safe for use in liver disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
It is advisable not to miss a dose of Thalidomide 50mg Capsule. If you miss a scheduled dose of these capsules, contact your doctor immediately.
It is used in the treatment of multiple myeloma and lepra reactions. This medicine kills the cancer cells and helps to prevent their growth in the body.
This capsule modulates the activity of the body’s immune system and helps in attacking the cancer cells.
Some common side effects are dizziness, chest pain, anxiety, headache, muscle weakness, sore throat, bleeding, pale skin, vomiting, etc.
It is important to take this medicine as prescribed by your doctor.
Follow your doctor’s advice about any restrictions on food and other activities.
1. Iyer, C. G. S., Languillon, J., Ramanujam, K., Tarabini-Castellani, G., De Las Aguas, J. T., Bechelli, L. M., ... & Sundaresan, T. (1971). WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bulletin of the World Health Organization, 45(6), 719.
2. Padhi, T., & Sethy, M. (2019). Lepra reactions. In Dermatological Emergencies (pp. 535-543). CRC Press.
3. Thompson, J. L., & Hansen, L. A. (2003). Thalidomide dosing in patients with relapsed or refractory multiple myeloma. Annals of Pharmacotherapy, 37(4), 571-576.
4. Mateos, M. V. (2010). Management of treatment-related adverse events in patients with multiple myeloma. Cancer treatment reviews, 36, S24-S32.
5. Hattori, Y., & Iguchi, T. (2004). Thalidomide for the treatment of multiple myeloma. Congenital anomalies, 44(3), 125-136.
fresenius kabi india
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.